Berry Genomics Co Ltd

Berry Genomics maintains a capital structure with a debt-to-equity ratio of 0.09, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.59, suggesting it can cover its short-term obligations but with limited surplus. The price-to-book ratio of 1.71 and the price-to-tangible-book ratio of 1.71 indicate that the market values the company's equity at a premium to its book value.

Profitability metrics for Berry Genomics are modest, with a return on equity of 0.0005 and a return on assets of 0.0004, both significantly below the industry benchmarks for medical equipment and services. The company's operating margin, calculated as operating income of 7,405,300 CNY on revenue of 272,299,770 CNY, is 2.72%, which is low compared to industry peers. Gross margin of 48.13% is derived from gross profit of 131,066,760 CNY on total revenue.

The company's revenue is primarily concentrated in its core genomic sequencing services and related products, with no disclosed geographic diversification in the provided data. This lack of geographic segmentation suggests a potential concentration risk, as the company's performance is tied to a single market or region.

Growth trajectory for Berry Genomics is constrained, with no specific numeric deltas provided for the current or next fiscal year. Historical revenue data shows a total of 272,299,770 CNY, but without comparative periods, it is difficult to assess year-over-year growth. The company's capital expenditure of -22,084,850 CNY indicates a net cash inflow from investing activities, which may suggest a reduction in capital spending or asset disposals.

Risk factors for Berry Genomics include a medium liquidity risk, as the company has negative net cash after subtracting total debt. The dilution risk is assessed as low, with no significant changes in shares outstanding between basic and diluted shares. The company's high price-to-earnings ratio of 3109.63 and ev-to-ebitda ratio of 453.75 suggest that the stock is highly valued relative to earnings and cash flow, which could be a concern for investors.

Recent events and filings for Berry Genomics are not detailed in the provided data, but the company's financial snapshot indicates a net income of 1,027,720 CNY, which is relatively low compared to its revenue and operating income. The operating cash flow of 13,195,640 CNY suggests the company generates positive cash from operations, which is a positive sign for its financial health.

Berry Genomics Co Ltd (000710.SZ) has undergone a significant structural update in its corporate classification, with its economic sector now formally identified as Healthcare and its primary activity defined as Healthcare Services & Equipment. This reclassification represents a medium-severity change in the company's tracked profile, establishing a clearer framework for understanding its operational focus within the broader market. Alongside the sectoral definition, the company’s risk assessment profile has been initialized with specific metrics. The dilution risk is currently assessed as low, indicating a stable capital structure regarding share issuance pressures. This assessment provides a baseline for evaluating the company's equity dynamics, suggesting that existing shareholders face minimal immediate threat from share count expansion. Conversely, the liquidity risk has been classified as medium. This designation highlights a moderate level of concern regarding the ease of trading the company's shares or the availability of capital, which is a critical factor for investors assessing market depth and potential volatility. The contrast between low dilution risk and medium liquidity risk offers a nuanced view of the company's financial stability versus its market tradability. These updates collectively refine the analytical view of Berry Genomics, moving from an undefined state to a structured profile with clear sectoral and risk parameters. While the company currently reports zero analyst coverage, index memberships, and top holders in the available data, the establishment of these foundational risk and classification metrics provides essential context for future financial analysis and investment decision-making.

Cash conversion of 12.84 is best-in-class, significantly outperforming the cohort median of 0.84.

Gross profit increased to 632 million CNY in FY-4, indicating improving operational efficiency and cost management.

Net loss narrowed significantly from 427 million CNY in FY-2 to 111 million CNY in FY-4.

Debt-to-equity ratio of 0.09 is below the cohort median of 0.2, suggesting a conservative capital structure.

The company faces high credit risk, posing significant potential for financial instability or default issues.

Free cash flow deteriorated to negative 360 million CNY in FY-4, worsening from negative 240 million CNY previously.

Return on equity of 0.05% is drastically below the cohort median of 1.42%, showing inefficient capital usage.

Revenue ¥1.42B; Operating income -¥115.5M.

• ▍Revenue ¥1.42B
• ▍Operating income -¥115.5M
• ▍Net margin -7.8%